Evidence map›Paper›PMID 29795804›Full record

ArticleChemical informatics (Wilmington, Del.)2017

High-Throughput Screening Assay Datasets from the PubChem Database.

Mariusz Butkiewicz, Yanli Wang, Stephen H Bryant, Edward W Lowe, David C Weaver, Jens Meiler

Abstract read
In one paragraph

Article in Chemical informatics (Wilmington, Del.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Drug Design-Past, Present, Future.Molecules (Basel, Switzerland) · 2022
    Review
  13. Article
  14. Deep Learning in Virtual Screening: Recent Applications and Developments.International journal of molecular sciences · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Frontiers in pharmacology · 2019
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mariusz ButkiewiczDepartment of Chemistry, Pharmacology and Biomedical Informatics, Center for Structural Biology, Institute of Chemical Biology, Vanderbilt University, Nashville, USA.
Yanli WangNational Institutes of Health, National Center for Biotechnology Information, US National Library of Medicine, Bethesda, USA.
Stephen H BryantNational Institutes of Health, National Center for Biotechnology Information, US National Library of Medicine, Bethesda, USA.
Edward W LoweDepartment of Chemistry, Pharmacology and Biomedical Informatics, Center for Structural Biology, Institute of Chemical Biology, Vanderbilt University, Nashville, USA.
David C WeaverDepartment of Chemistry, Pharmacology and Biomedical Informatics, Center for Structural Biology, Institute of Chemical Biology, Vanderbilt University, Nashville, USA.
Jens MeilerDepartment of Chemistry, Pharmacology and Biomedical Informatics, Center for Structural Biology, Institute of Chemical Biology, Vanderbilt University, Nashville, USA.

Funding

Membrane Protein Structure Elucidation from sparse NMR data (KAMP)R01GM080403 · NIGMS · VANDERBILT UNIVERSITY · PI MEILER, JENS · 2007 to 2019
$3.0M
Cheminformatics of Allosteric mGluR Modulation promotes Therapeutic DevelopmentR01MH090192 · NIMH · VANDERBILT UNIVERSITY · PI MEILER, JENS · 2010 to 2013
$1.5M
Computational Design of Protein-Ligand Interfaces - a Therapeutic StrategyR01GM099842 · NIGMS · VANDERBILT UNIVERSITY · PI MEILER, JENS · 2012 to 2015
$1.3M
Small Molecule Probes to Investigate Structure and Function of Y ReceptorsR01DK097376 · NIDDK · VANDERBILT UNIVERSITY · PI MEILER, JENS, WEAVER, C DAVID · 2013 to 2015
$1.0M
NIDDK NIH HHS R01 DK097376NIGMS NIH HHS R01 GM080403NIGMS NIH HHS R01 GM099842NIMH NIH HHS R01 MH090192
6 · The paper itself

Abstract

Availability of high-throughput screening (HTS) data in the public domain offers great potential to foster development of ligand-based computer-aided drug discovery (LB-CADD) methods crucial for drug discovery efforts in academia and industry. LB-CADD method development depends on high-quality HTS assay data, i.e., datasets that contain both active and inactive compounds. These active compounds are hits from primary screens that have been tested in concentration-response experiments and where the target-specificity of the hits has been validated through suitable secondary screening experiments. Publicly available HTS repositories such as PubChem often provide such data in a convoluted way: compounds that are classified as inactive need to be extracted from the primary screening record. However, compounds classified as active in the primary screening record are not suitable as a set of active compounds for LB-CADD experiments due to high false-positive rate. A suitable set of actives can be derived by carefully analysing results in often up to five or more assays that are used to confirm and classify the activity of compounds. These assays, in part, build on each other. However, often not all hit compounds from the previous screen have been tested. Sometimes a compound can be classified as 'active', though its meaning is 'inactive' on the target of interest as it is 'active' on a different target protein. Here, a curation process of hierarchically related confirmatory screens is illustrated based on two specifically chosen protein use-cases. The subsequent re-upload procedure into PubChem is described for the findings of those two scenarios. Further, we provide nine publicly accessible high quality datasets for future LB-CADD method development that provide a common baseline for comparison of future methods to the scientific community. We also provide a protocol researchers can follow to upload additional datasets for benchmarking.

Indexed as

DatasetsHTSLB-CADDPubChem

Identifiers

PMID29795804
PMCPMC5962024

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.